Blood test study aims to unlock secrets of lung cancer immunotherapy
NCT ID NCT06823401
First seen Feb 06, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study is for people with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body reacts to these treatments by looking for specific antibodies in the blood. The goal is to learn more about why some people respond better than others. About 270 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Tumori Regina Elena
ENROLLING_BY_INVITATIONRoma, RM, 000144, Italy
-
Istituto Tumori Regina Elena
RECRUITINGRoma, RM, 00128, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.